All News

RheumNow Podcast square

ERA, APPs, & Alpha GAL (3.21.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  Listen in for 2 new case questions - Ask Cush Anything.

Read Article
glomerulonephritis.GN_.lupus_.jpg

Mizoribine Effective in Lupus Nephritis

Jack Cush, MD

A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis. 

Read Article
2024.year.review

2024 Rheumatology Year in Review

Jack Cush, MD

2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.  While these many advances offer new hope, they are countered by disappointments and gapping unmet needs in rheumatology. Below is my top 10 list (in no particular order) of 2024 developments and desires that may change rheumatologic practices.

Read Article
RheumNow Podcast square

Hydroxychloro-King (3.7.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com

Read Article
Blood labs

Normalizing Serologies Enhances Remission in SLE

Jack Cush, MD

Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.

Read Article
AI,genes

SOCS1 Insufficiency - a Rare Inborn Error of Immunity

Jack Cush, MD

Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor signalling.

Read Article
Mizoribine Effective in Lupus Nephritis A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis. https://t.co/OS3yaJlEm7 https://t.co/1YcyfarF09

Links:

Dr. John Cush RheumNow ( View Tweet)
Congress Passes Fiscal Year 2025 Funding for Lupus Programs, including - $10 million Natl Lupus Patient Registry at CDC - $2 million Natl Lupus Training, Outreach, CTE Program - $47.08 billion for the National Institutes of Health SLE prgs https://t.co/BCs3lGdrXK https://t.co/58PkKG9ay6

Links:

Dr. John Cush RheumNow ( View Tweet)
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/qZb8OKjPpw https://t.co/Exr8u6QkNc

Links:

Dr. John Cush RheumNow ( View Tweet)
Polypharmacy (>=5Rx) studied in 81 RA & 30 SLE pts. Polypharmacy incr at 2 yrs ~44% to ~73%. Med adherence >85%. Polypharmacy NOT assoc w/ Dz activity in SLE, but in RA did correlate w/ better DAS28CRP score at one year https://t.co/Jw05DIrBym https://t.co/pLIoDvPj8i

Links:

Dr. John Cush RheumNow ( View Tweet)
Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/evsvf2GQiL https://t.co/J0Zl35FEHz
Dr. John Cush RheumNow ( View Tweet)
Full read review of Hydryoxychloroquine -its pharmacology, MOA (eg, blocking TLR 7 & 9), Dz specific efficacy and adverse effects https://t.co/N7XVbfnsfi https://t.co/yjKwcfugOJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/N4u4AUbdqH https://t.co/PotKfpOkH7

Links:

Dr. John Cush RheumNow ( View Tweet)
Available the first time: https://t.co/4UQlqwujiR 2025 On Demand! On Demand gives you access to all lectures, Q & A panels, and STEP talks, and all speaker slides and handouts — all packed with insights you won’t find anywhere else. Non-CME, practical, and finally here.… https://t.co/MHFUWb3az1 https://t.co/cqzZG40Xp5

Links:

Dr. John Cush RheumNow ( View Tweet)
Neuropsychiatric Lupus: More than just a headache Presentation by Dr. Daniel Carlson, at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/v0da4UNFNV https://t.co/BhBKOgak4W

Links:

Dr. John Cush RheumNow ( View Tweet)
Normalizing Serologies Enhances Remission in SLE Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd
Dr. John Cush RheumNow ( View Tweet)
Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK

Links:

Dr. John Cush RheumNow ( View Tweet)
Early Hydroxychloroquine Slows Cutaneous Lupus Progression A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl
Dr. John Cush RheumNow ( View Tweet)
Bubble Trouble - When Bullous Lupus Bursts onto the SLE Scene Presentation by Dr. Alana Haussmann at the Rheumatology Winter Clinical Symposia - Feb 2025 https://t.co/LRsT1TLEm4 https://t.co/bSi50pDn2O

Links:

Dr. John Cush RheumNow ( View Tweet)
Recurrent Pericarditis in Lupus A study from the Lupus Hopkins Cohort shows that systemic lupus erythematosus (SLE) patients with pericarditis are at risk for recurrence, and likely to be younger patients, with uncontrolled disease, and linkage to higher doses of oral… https://t.co/hML8NfhBy3 https://t.co/cKX5KaSg3a
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×